Vertex is one of the worse performing large cap biotechs over 6 mos. is getting boosted on a $152M royalty deal.
Biotech stocks continue to find buyers with the IBB ($211.70) approaching its 52 week all-time high of $213.
It is very difficult to find new picks better than our current portfolio or ETFs or FBIOX unless you want to speculate in small caps.
We still recommend avoiding mid-cap high fliers with low P/S or no Sales.